SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending downwards as shareholders discuss the potential impact of an upcoming share lock-up expiration, leading to concerns about possible insider selling and dilution. The community is debating entry points and whether the current price drop is an overreaction or a sign of further declines, with some viewing it as a buying opportunity while others express concern about the stock's future. Discussions also mention comparisons to similar situations with other stocks and speculation about potential manipulation.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to a definitive commercial agreement with Verizon to provide space-based cellular broadband, planned to start in 2026, which the community sees as a major validation of the technology. Community members are actively discussing the potential for a short squeeze and the long-term implications of the deal, while some express concern over a recent stock offering. The broader context involves the company's efforts to provide direct-to-device connectivity via satellite and compete with other players in the satellite communication space.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid news of an offtake agreement with REalloys, sparking bullish sentiment among investors who anticipate potential government involvement and a surge in stock value. The community is actively discussing the implications of this deal, potential short squeezes, and the company's strategic positioning in the rare earth element supply chain. Despite conflicting reports regarding government stakes, optimism persists due to the increasing demand for critical minerals and CRML's valuable assets.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending following a $75 million investment to accelerate growth in AI connectivity solutions, leading to community speculation about the investor's identity and strategic intentions. The community is focused on the potential impact of this investment on POET's market position, particularly in chip-to-chip communication and potential M&A activity within the AI hardware landscape. Key discussion points revolve around the company's partnerships and its capacity to alleviate bottlenecks in AI data centers.

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

TransCode Therapeutics Inc

RNAZ is trending due to its announcement of acquiring Polynoma and securing $25 million in financing, with the community actively discussing the potential impact of these developments. While some express optimism about the company's future and potential short squeeze opportunities given the low float, others are wary, pointing to past reverse splits and potential dilution. Discussions also revolve around the company's microRNA-based pipeline and upcoming Phase 2 trials.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals ($UPC) is trending due to discussions surrounding its low float and substantial cash reserves, leading to speculation about potential strategic moves. The community is drawing comparisons to other recent low-float runners, anticipating a similar breakout. Traders are closely monitoring for news catalysts that could trigger a significant price increase.

AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. Its portfolio includes first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. The company was founded by Gregory H. Bailey and James Mellon in 1973 and is headquartered in Road Town, British Virgin Islands.

AlphaTON Capital Corp.

AlphaTON Capital Corp is trending as community members discuss its low float and potential squeeze, particularly after news of the company tokenizing its mesothelioma treatment program. Traders are actively watching key price levels for breakouts, drawing comparisons to other recent low-float runners. The company's move to merge digital assets with oncology innovation is also sparking interest.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending as it reaches new 52-week highs, fueled by a new multi-launch agreement and overall bullish sentiment. The community is actively discussing upcoming catalysts like the Neutron launch and potential government contracts, contributing to the stock's momentum. Despite some profit-taking and analyst concerns about valuation, many investors remain optimistic about Rocket Lab's long-term growth potential in the expanding space economy.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the deep-sea mining sector gains attention, with community members discussing potential short squeezes and a possible breakout above the recent $8.66 high. Optimism is fueled by anticipation of government partnerships and regulatory approvals, particularly the NOAA decision. Bullish investors are focused on the company's long-term potential in the critical minerals market.

Fitell Corp. engages in the business of selling gym and fitness equipment. It also offers turnkey solution for personal training studios and commercial gym chains. Its brands include Muscle Motion, Rapid Motion, and FleetX. The company was founded in 2007 and is headquartered in Sydney, Australia.

Fitell Corp - Ordinary Shares - Class A

Fitell Corp

FTEL is trending as traders discuss its low float and recent Solana treasury expansion, noting the potential for a significant breakout. Community members are actively watching key price levels for entry points, drawing comparisons to other low-float runners. The stock's future direction remains a key point of discussion amidst the recent news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Serina Therapeutics surged 37% in after-hours trading on Monday after the company said the U.S. Food and Drug Administration (FDA) supported advancing its Parkinson’s drug candidate SER-252 (POZ-apomorphine) into a registrational clinical program.The stock ended Monday’s session down 0.2% at $5.64, but surged 37.2% to $7.74 in after-hours trading following the FDA update.The FDA feedback followed a recent Type B meeting and paves the way for Serina to move forward with a streamlined regulatory strategy.“People living with advanced Parkinson’s need more consistent relief from motor fluctuations and our data to date suggest that SER-252 may reliably improve daily function,” CEO Steve Ledger said, adding that the company’s plan is designed to be both rigorous and capital efficient.The proposed program will leverage prior knowledge of apomorphine while incorporating Serina’s POZ-enabled profile. According to the FDA’s feedback, Serina’s first study could be designed as part of its overall registrational trial program, subject to final documentation at the time of IND submission.Serina plans to submit a U.S. IND application in the fourth quarter of 2025 and begin dosing patients in Australia later this year, with the data expected to feed into the global registrational package. U.S. patient enrollment is anticipated to begin in the first quarter of 2026, once the IND is cleared.The planned SER-252-1b study will test the therapy in up to 88 adults with Parkinson’s disease and motor fluctuations, evaluating safety, tolerability, pharmacokinetics, and exploratory efficacy measures, including MDS-UPDRS motor scores.SER-252 is designed to provide continuous dopaminergic stimulation (CDS) via once- or twice-weekly subcutaneous injections, utilizing Enable Injections’ enFuse wearable delivery platform to enhance patient comfort and convenience.&nbsp;Serina believes its POZ drug optimization technology can help stabilize drug levels and reduce side effects compared with traditional therapies.Ledger said the FDA’s response also validated Serina’s broader pipeline ambitions: “The feedback provides early proof-of-principle for our platform, confirming that we can effectively align with the agency’s expectations for the 505(b)(2) NDA pathway.”On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested that Serina shares&nbsp;could continue to rise in the next session and said they were already “fully loaded.”<stembedurl>https://stocktwits.com/Santa34/message/626511634</stembedurl>Another user speculated whether Serina’s stock could reach $20 as soon as the next trading session.<stembedurl>https://stocktwits.com/darthttrader/message/626511005</stembedurl><a href="https://stocktwits.com/symbol/SER">Serina’s stock</a> has risen 12.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Serina’s stock (SER) has risen 12.6% so far in 2025. (Photo credit: Getty Images)

Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today?

The FDA backed advancing its Parkinson’s drug candidate SER-252 into a registrational clinical program, a move that retail traders said could fuel further gains.

Equity

Shares of Serina Therapeutics, Inc. surged over 15% in pre-market trading on Tuesday, positioning the clinical-stage biotech&nbsp;stock to hit its highest level in over a month.&nbsp;The jump follows Serina’s announcement of a $10 million equity financing agreement with strategic shareholder JuvVentures (UK), aimed at propelling its SER-252 program for advanced Parkinson’s disease into clinical trials.Under the deal, Serina will issue one million shares of common stock at $10 per share, a significant 120% premium to its Nov. 26 closing price and a 110% premium from Monday’s closing price.The financing is structured in two tranches, with the first $5 million tranche already received on Nov. 27, and the second tranche due by Jan. 31, 2025.&nbsp;The funds will support the advancement of SER-252, an investigational therapy developed using Serina’s proprietary drug optimization technology.&nbsp;Designed to deliver continuous dopaminergic stimulation (CDS), SER-252 aims to mitigate levodopa-related motor complications, such as dyskinesia, while increasing “on time” and reducing “off time” in patients with advanced Parkinson’s disease.&nbsp;The therapy integrates a wearable drug delivery platform, which provides long-acting subcutaneous delivery of CDS without causing skin reactions, enhancing both comfort and convenience for patients.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SET_sentiment_and_message_volume_on_Dec_3_premarket_ebfe4d174b.png" alt="SET sentiment and message volume on Dec 3 premarket.png" width="1318" height="318"><figcaption>SET sentiment and message volume on Dec 3 premarket as of 8:00 am ET | source: Stocktwits</figcaption></figure>Retail investors were quick to rally behind the stock on Stocktwits, where sentiment turned ‘extremely bullish’ before the opening bell, with message volume surging.&nbsp;<stembedurl>https://stocktwits.com/harry925/message/594787799</stembedurl>Still, Serina’s stock remains down over 67% year-to-date,For updates and corrections, email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-rises-after-upgrade-price-target-hikes/cJ9kq43RhE">Tesla Stock Rises After Massive Price Target Hikes On Trump, AI Factors: Retail’s Charged Up</a>

Under the deal, Serina will issue one million shares of common stock at $10 per share, a 110% premium from Monday’s closing price.

Serina Therapeutics Stock Soars Pre-Market On $10M Equity Deal To Fund Parkinson’s Trials: Retail Sentiment Explodes

The financing is structured in two tranches, with the first $5 million tranche already received on Nov. 27, and the second tranche due by Jan. 31, 2025. 

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

Serina Therapeutics Inc.

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

SER Serina Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest SER News